DAFTAR PUSTAKA

Alireza, Takzaree, Goodarzi Mehrdad, Rastegar Tayebeh, Shahbabaee Shakiba, and Takzaree Nasrin. 2020. "*Investigating Histopathologic the Synergistic Effect of Topical Use of Mentha Pulegium Essential Oil and Honey in Healing of Cutaneous Ulcers.*" *Journal of Medicinal Plants* 18(72):274–87.

Acton, C., & Dunwoody, G. 2008. *The use of medical grade honey in clinical practice.* British Journal of Nursing, vol 17 No 20

Agus, A. et al., 2019, Evaluation of antioxidant activity, phenolic, flavonoid and Vitamin C content of several honeys produced by the Indonesian stingless bee: Tetragonula laeviceps, Livestock Research for Rural Development., Vol. 31, No. 10

Al-Waili, N.S., Salom, K., & Al-Ghamdi,A, A. 2011. *Honey for wound healing, ulcer, and burn; data supporting its use in clinical practice.* The scientific journal 11 766-787.

Arnold MJ, Services U. *Obstetric Lacerations : Prevention And Repair.* 2021;

Bryant, A.R., Nix, P.D. (2007). *Acute & Chronic Wounds :* Current Management Concepts, Third Edition. St. Louis, Missouri. Mosby.

Dwijayanti, N., & Puspitasari, E. (2019)*. Gambaran Tingkat Pengetahuan Ibu Nifas tentang Perawatan Luka Perineum di RB Amanda Gamping Sleman.* Universitas 'Aisyiyah Yogyakarta.

Dewi Kasuma (2018)., Hubunganpantang Makanan Dan Personal Hygiene Dengan Penyembuhan Luka Perineumpada Ibu Nifas Di Klinik Niar Medan. Politeknik Kesehatan Kemenkes Medan Jurusan Kebidanan Medan Prodi D-IV

Erfandi, E. 2013., *Evolusi Manajemen Luka*. Jakarta: CV. Trans Info Media.

Emmasitah, Raya, I., Usman, A. N., Mauludiyah, I., & Prihartini, A. R. (2020). Uji FTIR Dan Uji Fitokimia Dari Madu Trigona Spp. Untuk Persiapan Suplemen Wanita Prakonsepsi. Jurnal Keperawatan Muhammadiyah, 1–6.

Firdayanti, N., 2014, *Asuhan Kebidanan Pada Masa Nifas,* Salemba Medika, Jakarta.

Ferreira, Isabel C. F. R., Edmur Aires, João C. M. Barreira, and Letícia M. Estevinho. 2007. "*Antioxidant Activity of Portuguese Honey Samples: Different Contributions of the Entire Honey and Phenolic Extract.*" *Food Chemistry* 114(4):1438–43.

Fuadah, Dina Zakiyyatul, Diana Rachmania, and Novita Yudik. 2015. "*Pengaruh Terapi Kompres Madu Terhadap Penyembuhan Luka Full Thicknes Skin Loss Pada Tikus Putih (Rattus Norvegicus) (The Effect Of Honey Compress Therapy Toward Skin Wound Healing For Full Thicknes Loss On Rattus Norvegicus)*." 2(2).

Ginting, Desideria Yosepha, Agnes Erna Uly Saragih Simarmata, Layari Tarigan, and Damayanti Damayanti. 2019. "*Pengaruh Vulva Hygiene Terhadap Penyembuhan Luka Heacting Robekan Jalan Lahir Pada Ibu Bersalin.*" *Jurnal Penelitian Kebidanan & Kespro* 2(1):22–26.

Goh R, Goh D, Ellepola H. *Perineal tears – A review.* 2018;47(1):35–8.

Gunawan, N. A. (2017). Madu : efektivitasnya untuk perawatan luka. *Iai*, *44*(2), 138–142.

.Handian FI. 2006. E*fektivitas perawatan menggunakan madu nektar flora dibandingkan dengan silver sulfadiazine terhadap penyembuhan luka bakar derajat 2 terinfeksi pada marmut [skripsi].* Malang: Fakultas Kedokteran Universitas Brawijaya.

Irianto, I. D. K., Purwanto, P., & Mardan, M. T. (2020). Aktivitas Antibakteri dan Uji Sifat Fisik Sediaan Gel Dekokta Sirih Hijau (Piper betle L.) Sebagai Alternatif Pengobatan Mastitis Sapi. *Majalah Farmaseutik*, *16*(2), 202. https://doi.org/10.22146/farmaseutik.v16i2.53793

Jansson MH, Franzén K, Hiyoshi A, Tegerstedt G, Dahlgren H, Nilsson K. *Risk Factors For Perineal And Vaginal Tears In Primiparous Women – The Prospective POPRACT-Cohort Study.* 2020;0:1–14.

Kamal Sodiq, Rohmayanti. 2015." *Implementasi Perawatan Luka Modern.* The [2 Nd] University Research Coloquium." Fakultas Ilmu Kesehatan, Universitas Muhammadiyah Magelang : ISSN 2407-9189.

Kalangi, S. J. (2012). *Khasiat Madu Pada Penyembuhan Luka Kulit. Jurnal Biomedik: JBM*, *4*(3).

Kwon H, Park HS, Shim J, Lee KW, Choi S, Choi GY. *Trial on the Efficacy of Hyaluronidase in Preventing Perineal Trauma in Nulliparous Women.* 2020;61(1):79–84.

Leliqia, N. P. E. et al., 2020, Aktivitas Antioksidan Kombinasi Fraksi Metanol Virgin Coconut Oil dan Madu Kele Bali dengan Metode DPPH (2 , 2- diphenyl -1- picrylhidrazyl), Journal of Pharmaceutical Science and Clinical Research., Vol. 2020, No. 2, 84–96.

Listinawati, L. 2013. *Asuhan Kebidanan Terkini Kegawatdaruratan Maternal Neonatal*. Jakarta: CV Trans Info Media

Malone, Michael and Gary Tsai. 2016. "*Wound Healing with Apitherapy: A Review of the Effects of Honey.*" *Journal of Apitherapy* 1(1):29

Molan, P.C. (2011). *The evidance and the rationale for the use of honey as woudn healing wound practice and research vol.* 19.

Mz, Arif, Fakultas Kedokteran, and Universitas Lampung. 2017. "P*engaruh Madu Terhadap Luka Bakar The Effects of Honey in Skin Burn.*" 7:71–74.

Nasution, M. F. W., & Muslimdjas, Y. (2021). *Uji Efektivitas Madu Konsentrasi 50% Dan 100% Dibandingkan Dengan Povidone Iodine Terhadap Penyembuhan Luka Sayat Pada Mencit (Mus Musculus)*. *JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia*, *8*(3), 47-53.

Nurhidayah, Irfanita. 2020. "*Efektivitas Penggunaan Madu Dalam Proses Penyembuhan Pada Luka Bakar Derajat Ii : Literatur Review Effectiveness Of The Use Of Honey In The Healing Process Of Second Degree Burns* : Literature Review." XI(3):6–11.

Oxorn, Harry (2003). *Ilmu Kebidanan Patologi & Fisiologi Persalinan. Human labor and birth.* Yayasan Essentia Medica. Jakarta

Pitriani, Risa and Rita Afni. 2019. "*Pencegahan Infeksi Perineum Dengan Perawatan Luka.*" 2(3):221–26.

Pontis, Jonierison Alves, Luiz Antonio, Mendonça Alves, Silvio José, and Adriana

Flach. 2014. "*Color , Phenolic and Flavonoid Content , and Antioxidant Activity of Honey from Color , Phenolic and Flavonoid Content , and Antioxidant Activity of Honey from Roraima , Brazil*." (March).

Puspita R, Oenzil F, Desmiwarti. Pengaruh Pemberian Madu Asli Hutan Situnjung Terhadap TNF α Dan Penyembuhan Luka Pada Tikus Galur Wstar Jantan. J Kesehatan Andalas. 2018;7(Supplement 2):30-3.

Rahmadi, A. 2019. *Kitab Pedoman Pengobatan Nabi: Konsep Sehat berdasarkan hadits dan medits*. WahyuQolbu.

Rao, Pasupuleti Visweswara, Kumara Thevan Krishnan, Naguib Salleh, and Siew Hua Gan. 2016. "*Biological and Therapeutic Effects of Honey Produced by Honey Bees and Stingless Bees: A Comparative Review*." *Revista Brasileira de Farmacognosia* 26(5):657–64.

Rini Haryani Ratih. 2020." *Pengetahuan Dan Sikap Ibu Nifas Tentang Perawatan Luka Perineum."* Jurnal Kesmas Asclepius, Volume 2, Nomor 1.

Sesanti, H., Hastuty, B., Kes, M., Purba, P. N., Fram, S., & Farm, M. (2018). *Uji Stabilitas Fisik Formulasi Sediaan Gel Ekstrak Daun Ketepeng Cina (Cassia Alata L) Dengan Gelling Agent Na Cmc Terhadap Staphylococcus Aureus ATCC 230840. 10, 22–27.*

Suranto, Adji. 2007. *Khasiat dan Manfaat Madu Herbal, Terapi Madu:* PT Agro Media Pustaka

Saifuddin. 2010. *Buku Panduan Praktis Pelayanan Kesehatan Maternal dan*

Neonatal. Jakarta : EGC.

Senol DK, Ph D, Aslan E. *The Effects Of Cold Application To The Perineum On Pain Relief After Vaginal Birth. Asian Nurs Res (Korean Soc Nurs Sci) [Internet].* 2017;11(4):276–82.

Swenson CW, Low LK, Kowalk KM, Fenner DF. *Randomized Trial Of 3 Techniques Of Perineal Skin Closure During Second-Degree Perineal Laceration Repair. J Midwifery Womens Heal.* 2019;64(5):567–77.

Syafrizal, A. Bratawinata., Sila., and M. Marji. 2012. *Jenis Lebah Kelutut (Trigona spp.) Di Hutan Pendidikan Lempake.* Mulawarman Scientific Vol. 11 No. 1. ISSN 1412-498.

Tasleem, Samiyah, Syed Baqir Shyum Naqvi, Saadat Ali Khan, and Khursheed Hashimi. 2011. "'*Honey Ointment': A Natural Remedy of Skin Wound Infections.*" Journal of Ayub Medical College, Abbottabad : JAMC 23(2):26–31.

Zahra, N. N., Muliasari, H., Andayani, Y., & Sudarma, I. M. (2021). Analisis Kadar Fenolik Total Dan Aktivitas Antiradikalbebas Madu Dan Propolis Trigona Sp. Asal Lombok Utara. *Analytical and Environment Chemistry, 6*(01), 74–82.

Zukkhruf, Naelaz, Wakhidatul Kiromah, Siti Lestari, and Dyah Puji Astuti. 2018. "P*enerapan Pemberian Madu Untuk Mempercepat Penyembuhan Luka Perineum Pada Ibu Post Partum Application Of Giving Honey To Accelerate The Perineal Wound The 8 Th University Res.*" The 8 Th University Research Colloquium 2018 Universitas Muhammadiyah Purwokerto 561–65.

Wiknjosastro, H. 2000. *Ilmu Kebidanan. Jakarta*: YBPSP

LAMPIRAN

LEMBAR OBSERVASI

A. Identitas Umum

Nama   :

Umur   :

Paritas   : Hamil (G)….. Melahirkan (P)…. Keguguran (A)…..

No.Hp   :

Alamat   :

B. Lembar Observasi

No	Item Penyembuhan	Hasil		
		Hari ke-1	Hari ke-3	Hari ke -5
1	Kemerahan *(Redness)*			
2	Pembengkakan *(Edema)*			
3	Bercak Perdarahan *(Ecchymosis)*			
4	Pengeluaran *(Discharge)*			
5	Penyatuan Luka (*Approximation*)			
	Jumlah			

Skoring skala REEDA

0   = Penyembuhan Luka Baik *(Good Wound Healing)*

1-5   = Penyembuhan Luka Kurang Baik *(Insufficient Wound Healing)*

>5   = Penyembukan Luka Buruk *(Poor Wound Healing*

Pedoman Penilaian Skala REEDA

Nilai	Redness (Kemerahan)	Edema (Pembengkakan)	Ecchymosis (Bercak Perdarahan)	Discharge (Pengeluaran)	Approximation (Penyatuan luka)
0	Tidak ada	Tidak ada	Tidak ada	Tidak ada	Tertutup
1	Kurang dari 0,25 cm pada kedua sisi laserasi	Pada perineum, <1 cm dari laserasi	Kurang dari 0,25 cm pada kedua sisi atau 0,25 pada satu sisi	Serum	Jarak kulit 3 mm atau kurang
2	Kurang dari 0,5 cm pada kedua sisi laserasi	Pada perineum dan atau vulva, antara 1-2 cm dari laserasi	0,25-1 cm pada kedua sisi atau 0,5-2 cm pada satu sisi	Serosanguinus	Terdapat jarak antara kulit dan lemak subcutan
3	Lebih dari 0,5 cm pada kedua sisi laserasi	Pada perineum dan atau vulva, > 2 cm dari laserasi	> 1 cm pada kedua sisi atau 2 cm pada satu sisi	Berdarah, purulent	Terdapat jarak antara kulit, lemak subcutan dan fascia

0   = Penyembuhan Luka Baik *(Good Wound Healing)*
1-5   = Penyembuhan Luka Kurang Baik *(Insufficient Wound Healing)*
>5   = Penyembukan Luka Buruk *(Poor Wound Healing)*

Lampiran

Personal Hygien

No	Pernyataan	Melakukan	Tidak dilakukan
1.	Sebelum merawat luka jahitan di kemaluan, ibu melakukan cuci tangandahulu.		
2.	Cara ibu melepas pembalut dari depan(kemaluan) kekebelakang (anus).		
3.	ibu melakukan cebok dari depan(kemaluan) ke belakang(anus).		
4.	Ibu menghindari cebok dengan airhangat/ berendam air.		
5.	Ibu cebok dengan air rebusan daun sirih.		
6.	Ibu cebok menggunakan air dan sabun.		
7.	Ibu memakai kasa yang ditetesi betadin kemudian diletakkan pada luka jahitan di kemaluan.		
8.	Ibu mengganti celana 2 kali atau lebih dalam satu hari.		
9.	Selesai cebok, kemaluan ibu selalu dikeringkan.		
10.	Selesai cebok atau merawat luka jahitan, ibu cuci tangan		

* Dewi Kasuma (2018)

SURAT IZIN PENELITIAN
Nomor: 050/313/ Bappeda Litbang/XI/ 2021

Memperhatikan Surat dari Kepala Badan Kesatuan Bangsa dan Politik Kota Bima, Nomor: 074/324/Kesbangpol/IX/2021, tanggal 27 September 2021 tentang Rekomendasi Penelitian, dengan ini diberikan izin untuk melaksanakan penelitian kepada:

Nama	:	**ASNIAH HARTINAH**
NIM	:	P102192029
Jurusan	:	Magister (S2) Ilmu Kebidanan
Judul	:	**"PEMBERIAN GEL MADU TRIGONA UNTUK PENYEMBUHAN LUKA PERINEUM PADA IBU POST PARTUM GRADE I DAN GRADE II"**
Lokasi Penelitian	:	Puskesmas Mpunda Kota Bima, Puskesmas Penanae Kota Bima
Waktu Penelitian	:	1 (Satu) Bulan

Izin Penelitian ini berlaku sejak tanggal 28 Oktober 2021 s.d 30 November 2021 dan dapat diperpanjang kembali sesuai kebutuhan.

Kepada yang bersangkutan selama melakukan penelitian diharap tetap berada di tempat penelitiannya. Segera setelah penelitian selesai, agar 1 (satu) eksemplar hasil penelitian disampaikan kepada Badan Perencanaan Pembangunan, Penelitian dan Pengembangan Daerah Kota Bima.

Demikian Surat Izin Penelitian ini agar dapat dipergunakan sebagaimana mestinya.

Kota Bima, 29 November 2021
an. Kepala
Kabid Penelitian dan Pengembangan,

AHMAD SURYANSYAH, SE
NIP. 198007052009011010

Tembusan disampaikan kepada Yth.:
1. Walikota Bima (sebagai laporan) di Raba-Bima;
2. Kepala Puskesmas Mpunda Kota Bima;
3. Kepala Puskesmas Penanae Kota Bima;
4. Rektor Universitas Hasanuddin Makassar;
5. Yang Bersangkutan;
6. Arsip.

Nomor	: 074 / 324/ Kesbangpol / IX / 2021	Kota Bima, 27 September 2021
Lampiran	: -	Kepada
Perihal	: **Rekomendasi Penelitian**	Yth. Kepala BAPPEDA LITBANG

Kota Bima
di-

Raba-Bima

Berdasarkan surat Rektor Universitas Hasanuddin Makassar. Nomor : 4288/UN4.8/PT.01.04/2021, Tanggal 15 September 2021. Perihal Permohonan Izin Penelitian, dengan ini disampaikan bahwa yang tersebut dibawah ini :

Nama	: **ASNIAH HARTINAH**
Nim	: P102192029
Program Studi	: Magister (S2) Ilmu Kebidanan
Alamat	: Kota Bima
Judul	: **"PEMBERIAN GEL MADU TRIGONA UNTUK PENYEMBUHAN LUKA PERINEUM PADA IBU POST PARTUM GRADE I DAN GRADE II".**
Tempat Penelitian	: Puskesmas Mpunda dan Puskesmas Penanae Kota Bima
Lama Penelitian	: 1 (satu) bulan TMT 28 September 2021 s.d. 27 Oktober 2021.

Sehubungan dengan hal tersebut dengan ini kami menyetujui kegiatan dimaksud dengan ketentuan sebagai berikut :

1. Setelah kegiatan penelitian selesai, yang bersangkutan harus melaporkan kepada Walikota Bima U.p. Kepala Badan Kesatuan Bangsa dan Politik Kota Bima.

2. Penelitian tidak akan menyimpang dari ijin yang diberikan.

3. Mentaati semua peraturan perundang-undangan yang berlaku dan mengindahkan adat istiadat daerah setempat.

4. Menyerahkan 1 (satu) examplar hasil penelitian (Skripsi) kepada Walikota Bima U.p. Kepala Badan Kesatuan Bangsa dan Politik Kota Bima.

Demikian untuk dimaklum seperlunya, terima kasih.

a.n. KEPALA BADAN
SEKRETARIS,

Drs. ABD. HARIS
Pembina Tk. I (IV/b)
Nip. 19640409 199003 1 011

Tembusan :

Yth : 1. Walikota Bima;
   2. Rektor Universitas HasanuddinMakassar;
   3. Yang bersangkutan

REKOMENDASI PERSETUJUAN ETIK
Nomor : 13/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 12 Januari 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21110727	No Sponsor Protokol		
Peneliti Utama	**Asniah Hartinah**	Sponsor		
Judul Peneliti	Pemberian Gel Madu Trigona Untuk Penyembuhan Luka Perineum Pada Ibu Post Partum Grade I Dan Grade II			
No Versi Protokol	2	Tanggal Versi	**11 Januari 2022**	
No Versi PSP	2	Tanggal Versi	**11 Januari 2022**	
Tempat Penelitian	Puskesmas Mpunda Kota Bima dan Puskesmas Penana'e			
Jenis Review	☐ Exempted ☐ Expedited ☒ Fullboard Tanggal **15 Desember 2021**	Masa Berlaku 12 Januari 2022 sampai 12 Januari 2023		Frekuensi review lanjutan
Ketua KEPK FKUH RSUH dan RSWS	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan		
Sekretaris KEPK FKUH RSUH dan RSWS	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan		

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

PEMERINTAH KOTA BIMA
BADAN PERENCANAAN PEMBANGUNAN,
PENELITIAN DAN PENGEMBANGAN DAERAH

Jalan Soekarno Hatta No. 2 Raba-Bima Telp./Fax. (0374)44088

SURAT IZIN PENELITIAN
Nomor: 050/313/ Bappeda Litbang/IX/ 2021

Memperhatikan Surat dari Kepala Badan Kesatuan Bangsa dan Politik Kota Bima, Nomor: 074/324/Kesbangpol/IX/2021, tanggal 27 September 2021 tentang Rekomendasi Penelitian, dengan ini diberikan izin untuk melaksanakan penelitian kepada:

Nama	:	**ASNIAH HARTINAH**
NIM	:	P102192029
Jurusan	:	Magister (S2) Ilmu Kebidanan
Judul	:	**"PEMBERIAN GEL MADU TRIGONA UNTUK PENYEMBUHAN LUKA PERINEUM PADA IBU POST PARTUM GRADE I DAN GRADE II"**
Lokasi Penelitian	:	Puskesmas Mpunda Kota Bima, Puskesmas Penanae Kota Bima
Waktu Penelitian	:	1 (Satu) Bulan

Izin Penelitian ini berlaku sejak tanggal 28 September 2021 s.d 27 Oktober 2021 dan dapat diperpanjang kembali sesuai kebutuhan.

Kepada yang bersangkutan selama melakukan penelitian diharap tetap berada di tempat penelitiannya. Segera setelah penelitian selesai, agar 1 (satu) eksemplar hasil penelitian disampaikan kepada Badan Perencanaan Pembangunan, Penelitian dan Pengembangan Daerah Kota Bima.

Demikian Surat Izin Penelitian ini agar dapat dipergunakan sebagaimana mestinya.

Kota Bima, 30 September 2021
a.n. Kepala
Kabid. Penelitian dan Pengembangan,

AHMAD SURYANSYAH, SE
NIP. 198007052009011010

Tembusan disampaikan kepada Yth.:
1. Walikota Bima (sebagai laporan) di Raba-Bima;
2. Kepala Puskesmas Mpunda Kota Bima;
3. Kepala Puskesmas Penanae Kota Bima;
4. Rektor Universitas Hasanuddin Makassar;
5. Yang Bersangkutan;
6. Arsip.

DOKUMENTASI

HASIL SPSS

1. Karakteristik Responden

Umur

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Resiko R	15	75.0	75.0	75.0
	Resiko T	5	25.0	25.0	100.0
	Total	20	100.0	100.0	

Hasil Uji chi-square Berdasarkan umur dan Penyembuhan luka Gel 100%

Crosstab

			Penyembuhan_LukaGel100		Total
			Baik	Kurang	
Gel_100	Resdah	Expected Count	.5	1.5	2.0
		% within Gel_100	50.0%	50.0%	100.0%
	Resti	Expected Count	.5	1.5	2.0
		% within Gel_100	0.0%	100.0%	100.0%
Total		Expected Count	1.0	3.0	4.0
		% within Gel_100	25.0%	75.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.333[a]	1	.248		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	1.726	1	.189		
Fisher's Exact Test				1.000	.500
Linear-by-Linear Association	1.000	1	.317		
N of Valid Cases	4				

a. 4 cells (100.0%) have expected count less than 5. The minimum expected count is .50.

b. Computed only for a 2x2 table

Hasil Uji chi-square Berdasarkan umur dan Penyembuhan luka Gel 70%

Crosstab

			Penyembuhan_LukaGel100		Total
			Baik	Kurang	
Gel_70	Resdah	Expected Count	.5	1.5	2.0
		% within Gel_70	50.0%	50.0%	100.0%
	Resti	Expected Count	.5	1.5	2.0
		% within Gel_70	0.0%	100.0%	100.0%
Total		Expected Count	1.0	3.0	4.0
		% within Gel_70	25.0%	75.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.333[a]	1	.248		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	1.726	1	.189		
Fisher's Exact Test				1.000	.500
Linear-by-Linear Association	1.000	1	.317		
N of Valid Cases	4				

a. 4 cells (100.0%) have expected count less than 5. The minimum expected count is .50.

b. Computed only for a 2x2 table

Hasil Uji chi-square Berdasarkan umur dan Penyembuhan luka Gel 30%

Crosstab

			Penyembuhan_LukaGel100		Total
			Baik	Kurang	
Gel_30	Resdah	Expected Count	.5	1.5	2.0
		% within Gel_30	50.0%	50.0%	100.0%
	Resti	Expected Count	.5	1.5	2.0
		% within Gel_30	0.0%	100.0%	100.0%
Total		Expected Count	1.0	3.0	4.0
		% within Gel_30	25.0%	75.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.333[a]	1	.248		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	1.726	1	.189		
Fisher's Exact Test				1.000	.500
Linear-by-Linear Association	1.000	1	.317		
N of Valid Cases	4				

a. 4 cells (100.0%) have expected count less than 5. The minimum expected count is .50.

b. Computed only for a 2x2 table

Paritas

		Frequency	Percent	Valid Percent	Cumulative Percent
	Multi	9	45.0	45.0	45.0
Valid	Primi	11	55.0	55.0	100.0
	Total	20	100.0	100.0	

Hasil Uji chi-square Berdasarkan Paritas dan Penyembuhan luka Gel 100%

Crosstab

			Penyembuhan_LukaGel100		Total
			Baik	Kurang	
Gel_100	Primi	Expected Count	.5	1.5	2.0
		% within Gel_100	50.0%	50.0%	100.0%
	Multi	Expected Count	.5	1.5	2.0
		% within Gel_100	0.0%	100.0%	100.0%
Total		Expected Count	1.0	3.0	4.0
		% within Gel_100	25.0%	75.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.333[a]	1	.248		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	1.726	1	.189		
Fisher's Exact Test				1.000	.500
Linear-by-Linear Association	1.000	1	.317		
N of Valid Cases	4				

a. 4 cells (100.0%) have expected count less than 5. The minimum expected count is .50.

b. Computed only for a 2x2 table

Hasil Uji chi-square Berdasarkan Paritas dan Penyembuhan luka Gel 70%

Crosstab

			Penyembuhan_LukaGel100		Total
			Baik	Kurang	
Gel_70	Primi	Expected Count	.8	2.3	3.0
		% within Gel_70	33.3%	66.7%	100.0%
	Multi	Expected Count	.3	.8	1.0
		% within Gel_70	0.0%	100.0%	100.0%
Total		Expected Count	1.0	3.0	4.0
		% within Gel_70	25.0%	75.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.444[a]	1	.505		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	.680	1	.410		
Fisher's Exact Test				1.000	.750
Linear-by-Linear Association	.333	1	.564		
N of Valid Cases	4				

a. 4 cells (100.0%) have expected count less than 5. The minimum expected count is .25.

b. Computed only for a 2x2 table

Hasil Uji chi-square Berdasarkan Paritas dan Penyembuhan luka Gel 30%

Crosstab

			Penyembuhan_LukaGel100		Total
			Baik	Kurang	
Gel_30	Primi	Expected Count	.3	.8	1.0
		% within Gel_30	100.0%	0.0%	100.0%
	Multi	Expected Count	.8	2.3	3.0
		% within Gel_30	0.0%	100.0%	100.0%
Total		Expected Count	1.0	3.0	4.0
		% within Gel_30	25.0%	75.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	4.000[a]	1	.046		
Continuity Correction[b]	.444	1	.505		
Likelihood Ratio	4.499	1	.034		
Fisher's Exact Test				.250	.250
Linear-by-Linear Association	3.000	1	.083		
N of Valid Cases	4				

a. 4 cells (100.0%) have expected count less than 5. The minimum expected count is .25.

b. Computed only for a 2x2 table

Personal_Hygien

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Melakuka	19	95.0	95.0	95.0
	Tidak	1	5.0	5.0	100.0
	Total	20	100.0	100.0	

Hasil Uji chi-square Berdasarkan *Personal Hygien* dan Penyembuhan luka Gel 100%

Crosstab

			Penyembuhan_LukaGel100		Total
			Baik	Kurang	
Gel_100	Melakukan	Expected Count	1.0	3.0	4.0
		% within Gel_100	25.0%	75.0%	100.0%
Total		Expected Count	1.0	3.0	4.0
		% within Gel_100	25.0%	75.0%	100.0%

Chi-Square Tests

	Value
Pearson Chi-Square	.^{a}
N of Valid Cases	4

a. No statistics are computed because Gel_100 is a constant.

Hasil Uji chi-square Berdasarkan *Personal Hygien* dan Penyembuhan luka Gel 70%

Crosstab

			Penyembuhan_LukaGel100		Total
			Baik	Kurang	
Gel_70	Melakukan	Expected Count	.8	2.3	3.0
		% within Gel_70	33.3%	66.7%	100.0%
	Tidak Melakukan	Expected Count	.3	.8	1.0
		% within Gel_70	0.0%	100.0%	100.0%
Total		Expected Count	1.0	3.0	4.0
		% within Gel_70	25.0%	75.0%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.444^{a}	1	.505		
Continuity Correction^{b}	.000	1	1.000		
Likelihood Ratio	.680	1	.410		

					1.000	.750
Fisher's Exact Test						
Linear-by-Linear Association	.333	1	.564			
N of Valid Cases	4					

a. 4 cells (100.0%) have expected count less than 5. The minimum expected count is .25.

b. Computed only for a 2x2 table

Hasil Uji chi-square Berdasarkan *Personal Hygien* dan Penyembuhan luka Gel 30%

Crosstab

		Penyembuhan_LukaGel100		Total
		Baik	Kurang	
Gel_30 Melakukan	Expected Count	1.0	3.0	4.0
	% within Gel_30	25.0%	75.0%	100.0%
Total	Expected Count	1.0	3.0	4.0
	% within Gel_30	25.0%	75.0%	100.0%

Chi-Square Tests

	Value
Pearson Chi-Square	.a
N of Valid Cases	4

a. No statistics are computed

because Gel_30 is a constant.

2. UJI NORMALITAS

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Pre Tampa Madu	.329	4	.	.895	4	.406
Post Tampa Madu	.301	4	.	.897	4	.414
Pre Gel 100%	.192	4	.	.971	4	.850
Post Gel 100%	.283	4	.	.863	4	.272
Pre Gel 70%	.283	4	.	.863	4	.272
Post Gel 70%	.303	4	.	.791	4	.086
Pre Gel 30%	.364	4	.	.840	4	.195
Pre Gel 30%	.162	4	.	.989	4	.952
Pre Bioplasenta	.250	4	.	.945	4	.683
Post Bioplasenta	.214	4	.	.963	4	.798
Hari k-3 GTM	.151	4	.	.993	4	.972

Hari k-5 GTM	.288	4	.	.887	4	.369
Hari k-3 Gel 100%	.250	4	.	.945	4	.683
Hari k-5 Gel 100%	.283	4	.	.863	4	.272
Hari k-3 Gel 70%	.192	4	.	.971	4	.850
Hari k-5 Gel 70%	.283	4	.	.863	4	.272
Hari k-3 Gel 30%	.250	4	.	.945	4	.683
Hari k-5 Gel 30%	.192	4	.	.971	4	.850
Hari k-3 Bioplasenta	.329	4	.	.895	4	.406
Hari k-5 Bioplasenta	.181	4	.	.991	4	.962

a. Lilliefors Significance Correction

3. UJI Paired Samples T-test

Hari 1-7 Tanpa Pemberian Gel madu

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre Tampa Madu	13.25	4	1.258	.629
	Post Tampa Madu	13.50	4	3.873	1.936

Paired Samples Test

	Paired Differences					t	df	Sig. (2-tailed)
	Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
				Lower	Upper			
Pair 1 Pre Tampa Madu - Post Tampa Madu	-.250	2.872	1.436	-4.820	4.320	-.174	3	.873

Hari 3-5 Tanpa Pemberian Gel madu

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre Tampa Madu	13.25	4	1.258	.629
	Hari k-5 GTM	13.25	4	2.630	1.315

Paired Samples Test

	Paired Differences	t	df	Sig. (2-

		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				tailed)
					Lower	Upper			
Pair 1	Pre Tampa Madu - Hari k-5 GTM	.000	1.414	.707	-2.250	2.250	.000	3	1.000

Hari 1-7 Gel 100%

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre Gel 100%	15.25	4	1.708	.854
	Post Gel 100%	.75	4	.957	.479

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Pre Gel 100% - Post Gel 100%	14.500	1.732	.866	11.744	17.256	16.743	3	.000

Hari 3-5 Gel 100%

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre Gel 100%	15.25	4	1.708	.854
	Hari k-5 Gel 100%	1.25	4	.957	.479

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			

Pair 1	Pre Gel 100% - Hari k-5 Gel 100%	14.000	1.155	.577	12.163	15.837	24.249	3	.000

Hari 1-7 Gel 70%

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre Gel 70%	16.25	4	.957	.479
	Post Gel 70%	3.75	4	1.893	.946

Paired Samples Test

		Paired Differences					t	df	Sig.
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Pre Gel 70% - Post Gel 70%	12.500	2.082	1.041	9.188	15.812	12.010	3	

Hari 3-5 Gel 70%

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre Gel 70%	16.25	4	.957	.479
	Hari k-5 Gel 70%	7.50	4	1.915	.957

Paired Samples Test

	Paired Differences					t	df	Sig. (2-tailed)
	Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
				Lower	Upper			

Pair 1	Pre Gel 70% - Hari k-5 Gel 70%	8.750	1.258	.629	6.748	10.752	13.908	3	.001

Hari 1-7 Gel 30%

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre Gel 30%	14.50	4	1.732	.866
	Pre Gel 30%	10.75	4	2.986	1.493

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Pre Gel 30% - Pre Gel 30%	3.750	2.217	1.109	.222	7.278	3.382	3	.043

Hari 3-5 Gel 30%

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre Gel 30%	14.50	4	1.732	.866
	Hari k-5 Gel 30%	11.75	4	1.708	.854

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Pre Gel 30% - Hari k-5 Gel 30%	2.750	2.363	1.181	-1.010	6.510	2.328	3	.102

Hari 1-7 Pemberian Bioplasenta

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre Bioplasenta	15.00	4	.816	.408
	Post Bioplasenta	8.75	4	2.217	1.109

Paired Samples Test

		Paired Differences					t	df	
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Pre Bioplasenta - Post Bioplasenta	6.250	1.708	.854	3.532	8.968	7.319	3	

Hari 3-5 Pemberian Bioplasenta

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Pre Bioplasenta	15.00	4	.816	.408
	Hari k-5 Bioplasenta	11.50	4	2.887	1.443

Paired Samples Test

		Paired Differences					t	df	Sig. (2-tailed)
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
					Lower	Upper			
Pair 1	Pre Bioplasenta - Hari k-5 Bioplasenta	3.500	2.887	1.443	-1.093	8.093	2.425	3	.094

4. UJI *Repeated Measure Anova*

Repeated Measure Anova Tanpa Pemberian

Within-Subjects Factors

Measure:MEASURE_1

hari	Dependent Variable
1	hari_1
2	hari_3
3	hari_5
4	hari_7

Mauchly's Test of Sphericity[b]

Measure:MEASURE_1

Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Greenhouse-Geisser	Huynh-Feldt	Lower-bound
					Epsilon[a]		
hari	.000	.	5	.	.549	1.000	.333

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an identity matrix.

a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of Within-Subjects Effects table.

b. Design: Intercept
 Within Subjects Design: hari

Tests of Within-Subjects Effects

Measure:MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
hari	Sphericity Assumed	2.250	3	.750	.325	.807
	Greenhouse-Geisser	2.250	1.646	1.367	.325	.699
	Huynh-Feldt	2.250	3.000	.750	.325	.807
	Lower-bound	2.250	1.000	2.250	.325	.608
Error(hari)	Sphericity Assumed	20.750	9	2.306		
	Greenhouse-Geisser	20.750	4.938	4.202		
	Huynh-Feldt	20.750	9.000	2.306		
	Lower-bound	20.750	3.000	6.917		

Estimates

Measure:MEASURE_1

hari	Mean	Std. Error	95% Confidence Interval	
			Lower Bound	Upper Bound
1	13.250	.629	11.248	15.252
2	12.500	.645	10.446	14.554
3	13.250	1.315	9.065	17.435
4	13.500	1.936	7.337	19.663

Pairwise Comparisons

Measure:MEASURE_1

(I) hari	(J) hari	Mean Difference (I-J)	Std. Error	Sig.[a]	95% Confidence Interval for Difference[a]	
					Lower Bound	Upper Bound
1	2	.750	.479	1.000	-2.233	3.733
	3	.000	.707	1.000	-4.406	4.406
	4	-.250	1.436	1.000	-9.199	8.699
2	1	-.750	.479	1.000	-3.733	2.233
	3	-.750	1.031	1.000	-7.173	5.673
	4	-1.000	1.354	1.000	-9.438	7.438
3	1	.000	.707	1.000	-4.406	4.406
	2	.750	1.031	1.000	-5.673	7.173
	4	-.250	1.109	1.000	-7.159	6.659
4	1	.250	1.436	1.000	-8.699	9.199
	2	1.000	1.354	1.000	-7.438	9.438
	3	.250	1.109	1.000	-6.659	7.159

Based on estimated marginal means

a. Adjustment for multiple comparisons: Bonferroni.

Repeated Measure Anova Gel 100%

Within-Subjects Factors

Measure:MEASURE_1

hari	Dependent Variable
1	hari_1_pre
2	Hari_3
3	Hari_5
4	Hari_7

Mauchly's Test of Sphericity[b]

Measure:MEASURE_1

| Within Subjects Effect | Mauchly's W | Approx. Chi-Square | df | Sig. | Epsilon[a] | | |
					Greenhouse-Geisser	Huynh-Feldt	Lower-bound
hari	.040	5.545	5	.420	.488	.836	.333

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an identity matrix.

a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of Within-Subjects Effects table.

b. Design: Intercept
 Within Subjects Design: hari

Tests of Within-Subjects Effects

Measure:MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Hari	Sphericity Assumed	556.250	3	185.417	91.438	.000
	Greenhouse-Geisser	556.250	1.464	380.054	91.438	.000
	Huynh-Feldt	556.250	2.509	221.723	91.438	.000
	Lower-bound	556.250	1.000	556.250	91.438	.002
Error(hari)	Sphericity Assumed	18.250	9	2.028		
	Greenhouse-Geisser	18.250	4.391	4.156		
	Huynh-Feldt	18.250	7.526	2.425		
	Lower-bound	18.250	3.000	6.083		

Tests of Within-Subjects Effects

Measure:MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
hari	Sphericity Assumed	556.250	3	185.417	91.438	.000
	Greenhouse-Geisser	556.250	1.464	380.054	91.438	.000
	Huynh-Feldt	556.250	2.509	221.723	91.438	.000
	Lower-bound	556.250	1.000	556.250	91.438	.002
Error(hari)	Sphericity Assumed	18.250	9	2.028		
	Greenhouse-Geisser	18.250	4.391	4.156		

| | Huynh-Feldt | 18.250 | 7.526 | 2.425 | | |
| | Lower-bound | 18.250 | 3.000 | 6.083 | | |

Estimates

Measure:MEASURE_1

hari	Mean	Std. Error	95% Confidence Interval	
			Lower Bound	Upper Bound
1	15.250	.854	12.532	17.968
2	3.000	.816	.402	5.598
3	1.250	.479	-.273	2.773
4	1.000	.408	-.299	2.299

Pairwise Comparisons

Measure:MEASURE_1

(I) hari	(J) hari	Mean Difference (I-J)	Std. Error	Sig.[a]	95% Confidence Interval for Difference[a]	
					Lower Bound	Upper Bound
1	2	12.250[*]	1.436	.020	3.301	21.199
	3	14.000[*]	.577	.001	10.402	17.598
	4	14.250[*]	.750	.002	9.576	18.924
2	1	-12.250[*]	1.436	.020	-21.199	-3.301
	3	1.750	1.250	1.000	-6.039	9.539
	4	2.000	1.225	1.000	-5.632	9.632
3	1	-14.000[*]	.577	.001	-17.598	-10.402
	2	-1.750	1.250	1.000	-9.539	6.039
	4	.250	.250	1.000	-1.308	1.808
4	1	-14.250[*]	.750	.002	-18.924	-9.576
	2	-2.000	1.225	1.000	-9.632	5.632
	3	-.250	.250	1.000	-1.808	1.308

Based on estimated marginal means

*. The mean difference is significant at the ,05 level.

a. Adjustment for multiple comparisons: Bonferroni.

Repeated Measure Anova Gel 70%

Within-Subjects Factors

Measure:MEASURE_1

hari	Dependent Variable
1	hari_1
2	hari_3
3	hari_5
4	hari_7

Mauchly's Test of Sphericity[b]

Measure:MEASURE_1

Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[a]		
					Greenhouse-Geisser	Huynh-Feldt	Lower-bound
hari	.603	.871	5	.977	.785	1.000	.333

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an identity matrix.

a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of Within-Subjects Effects table.

b. Design: Intercept
 Within Subjects Design: hari

Tests of Within-Subjects Effects

Measure:MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
Hari	Sphericity Assumed	336.688	3	112.229	57.512	.000
	Greenhouse-Geisser	336.688	2.356	142.933	57.512	.000
	Huynh-Feldt	336.688	3.000	112.229	57.512	.000
	Lower-bound	336.688	1.000	336.688	57.512	.005
Error(hari)	Sphericity Assumed	17.563	9	1.951		
	Greenhouse-Geisser	17.563	7.067	2.485		
	Huynh-Feldt	17.563	9.000	1.951		
	Lower-bound	17.563	3.000	5.854		

Estimates

Measure:MEASURE_1

hari	Mean	Std. Error	95% Confidence Interval	
			Lower Bound	Upper Bound
1	16.250	.479	14.727	17.773
2	10.750	.854	8.032	13.468
3	7.500	.957	4.453	10.547
4	3.750	.946	.738	6.762

Pairwise Comparisons

Measure:MEASURE_1

(I) hari	(J) hari	Mean Difference (I-J)	Std. Error	Sig.[a]	95% Confidence Interval for Difference[a]	
					Lower Bound	Upper Bound
1	2	5.500	.957	.063	-.466	11.466
	3	8.750[*]	.629	.005	4.829	12.671
	4	12.500[*]	1.041	.007	6.014	18.986
2	1	-5.500	.957	.063	-11.466	.466
	3	3.250	.854	.191	-2.071	8.571
	4	7.000	1.225	.064	-.632	14.632
3	1	-8.750[*]	.629	.005	-12.671	-4.829
	2	-3.250	.854	.191	-8.571	2.071
	4	3.750	1.109	.258	-3.159	10.659
4	1	-12.500[*]	1.041	.007	-18.986	-6.014
	2	-7.000	1.225	.064	-14.632	.632
	3	-3.750	1.109	.258	-10.659	3.159

Based on estimated marginal means

a. Adjustment for multiple comparisons: Bonferroni.

*. The mean difference is significant at the ,05 level.

Repeated Measure Anova Gel 30%

Within-Subjects Factors

Measure:MEASURE_1

hari	Dependent Variable
1	hari_1
2	hari_3
3	hari_5
4	hari_7

Mauchly's Test of Sphericity[b]

Measure:MEASURE_1

Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[a]		
					Greenhouse-Geisser	Huynh-Feldt	Lower-bound
hari	.005	8.962	5	.162	.662	1.000	.333

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an identity matrix.

a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of Within-Subjects Effects table.

b. Design: Intercept
 Within Subjects Design: hari

Tests of Within-Subjects Effects

Measure:MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
hari	Sphericity Assumed	30.500	3	10.167	5.382	.021
	Greenhouse-Geisser	30.500	1.986	15.356	5.382	.046
	Huynh-Feldt	30.500	3.000	10.167	5.382	.021
	Lower-bound	30.500	1.000	30.500	5.382	.103
Error(hari)	Sphericity Assumed	17.000	9	1.889		
	Greenhouse-Geisser	17.000	5.959	2.853		
	Huynh-Feldt	17.000	9.000	1.889		
	Lower-bound	17.000	3.000	5.667		

Estimates

Measure:MEASURE_1

hari	Mean	Std. Error	95% Confidence Interval	
			Lower Bound	Upper Bound
1	14.500	.866	11.744	17.256
2	12.000	.408	10.701	13.299
3	11.750	.854	9.032	14.468
4	10.750	1.493	5.998	15.502

Pairwise Comparisons

Measure:MEASURE_1

(I) hari	(J) hari	Mean Difference (I-J)	Std. Error	Sig.[a]	95% Confidence Interval for Difference[a]	
					Lower Bound	Upper Bound
1	2	2.500	.645	.183	-1.522	6.522
	3	2.750	1.181	.614	-4.612	10.112
	4	3.750	1.109	.258	-3.159	10.659
2	1	-2.500	.645	.183	-6.522	1.522
	3	.250	.629	1.000	-3.671	4.171
	4	1.250	1.109	1.000	-5.659	8.159
3	1	-2.750	1.181	.614	-10.112	4.612
	2	-.250	.629	1.000	-4.171	3.671
	4	1.000	1.000	1.000	-5.232	7.232
4	1	-3.750	1.109	.258	-10.659	3.159
	2	-1.250	1.109	1.000	-8.159	5.659
	3	-1.000	1.000	1.000	-7.232	5.232

Based on estimated marginal means

a. Adjustment for multiple comparisons: Bonferroni.

Repeated Measure Anova Bioplasenta

Within-Subjects Factors

Measure:MEASURE_1

hari	Dependent Variable
1	hari_1
2	hari_3
3	hari_5
4	hari_7

Mauchly's Test of Sphericity[b]

Measure:MEASURE_1

Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Greenhouse-Geisser	Huynh-Feldt	Lower-bound
					Epsilon[a]		
hari	.016	7.149	5	.274	.594	1.000	.333

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an identity matrix.

a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of Within-Subjects Effects table.

b. Design: Intercept
 Within Subjects Design: hari

Tests of Within-Subjects Effects

Measure:MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.
hari	Sphericity Assumed	90.500	3	30.167	14.289	.001
	Greenhouse-Geisser	90.500	1.783	50.765	14.289	.008
	Huynh-Feldt	90.500	3.000	30.167	14.289	.001
	Lower-bound	90.500	1.000	90.500	14.289	.032
Error(hari)	Sphericity Assumed	19.000	9	2.111		
	Greenhouse-Geisser	19.000	5.348	3.553		
	Huynh-Feldt	19.000	9.000	2.111		
	Lower-bound	19.000	3.000	6.333		

Estimates

Measure:MEASURE_1

hari	Mean	Std. Error	95% Confidence Interval	
			Lower Bound	Upper Bound
1	15.000	.408	13.701	16.299
2	13.750	.629	11.748	15.752
3	11.500	1.443	6.907	16.093
4	8.750	1.109	5.222	12.278

Pairwise Comparisons

Measure:MEASURE_1

(I) hari	(J) hari	Mean Difference (I-J)	Std. Error	Sig.[a]	95% Confidence Interval for Difference[a]	
					Lower Bound	Upper Bound
1	2	1.250	.750	1.000	-3.424	5.924
	3	3.500	1.443	.563	-5.494	12.494
	4	6.250[*]	.854	.032	.929	11.571
2	1	-1.250	.750	1.000	-5.924	3.424
	3	2.250	.854	.468	-3.071	7.571
	4	5.000	1.000	.092	-1.232	11.232
3	1	-3.500	1.443	.563	-12.494	5.494
	2	-2.250	.854	.468	-7.571	3.071
	4	2.750	1.109	.535	-4.159	9.659
4	1	-6.250[*]	.854	.032	-11.571	-.929
	2	-5.000	1.000	.092	-11.232	1.232
	3	-2.750	1.109	.535	-9.659	4.159

Based on estimated marginal means

a. Adjustment for multiple comparisons: Bonferroni.

*. The mean difference is significant at the ,05 level.

5. UJI *Repeated Oneway Anova*

Descriptives

Gel

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum
					Lower Bound	Upper Bound		
Tampa Gel	4	13.50	3.873	1.936	7.34	19.66	10	19
Gel Madu 100%	4	.75	.957	.479	-.77	2.27	0	2
Gel Madu 70%	4	3.75	1.893	.946	.74	6.76	1	5
Gel Madu 30%	4	10.75	2.986	1.493	6.00	15.50	7	14
Bioplasenta	4	8.75	2.217	1.109	5.22	12.28	6	11
Total	20	7.50	5.287	1.182	5.03	9.97	0	19

ANOVA

Gel

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	431.000	4	107.750	16.163	.000
Within Groups	100.000	15	6.667		
Total	531.000	19			

Gel

Tukey HSD

Pemberian	N	Subset for alpha = 0.05		
		1	2	3
Gel Madu 100%	4	.75		
Gel Madu 70%	4	3.75	3.75	
Bioplasenta	4		8.75	8.75
Gel Madu 30%	4			10.75
Tampa Gel	4			13.50
Sig.		.495	.094	.120

Means for groups in homogeneous subsets are displayed.

a. Uses Harmonic Mean Sample Size = 4.000.